The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib was developed by the experts of the Russian Association of Endocrinologists and the Russian Society of Clinical Oncology. The consensus contains recommendation o...
Enregistré dans:
Auteurs principaux: | Natalya V. Mazurina, Elena V. Artamonova, Maria F. Beloyartseva, Ekaterina I. Volkova, Inna P. Ganshina, Ekaterina A. Troshina, Sergey A. Tjulandin, Viacheslav A. Chubenko |
---|---|
Format: | article |
Langue: | RU |
Publié: |
IP Habib O.N.
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/95b6d9b471d74d51ad5bf1e4d91f076f |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data
par: Armaghani AJ, et autres
Publié: (2020) -
The frequency and spectrum of PIK3CA mutations in patients with estrogen receptor-positive HER2-negative advanced breast cancer residing in various regions of Russia
par: Tatiana N. Sokolova, et autres
Publié: (2021) -
Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives
par: Chang DY, et autres
Publié: (2021) -
The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review
par: Irina V. Poddubnaya, et autres
Publié: (2021) -
PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
par: Editorial Board
Publié: (2021)